Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Up 383.3% in January

Vincerx Pharma, Inc. (NASDAQ:VINC) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 269,200 shares, an increase of 383.3% from the January 15th total of 55,700 shares. Approximately 14.6% of the company’s stock are sold short. Based on an average trading volume of 691,100 shares, the days-to-cover ratio is currently 0.4 days.

Vincerx Pharma Stock Down 6.7 %

Shares of VINC opened at $1.25 on Thursday. Vincerx Pharma has a twelve month low of $1.24 and a twelve month high of $187.44. The stock has a market capitalization of $2.80 million, a P/E ratio of -0.06 and a beta of 1.37. The company has a 50 day moving average of $3.25 and a 200-day moving average of $8.01.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.